LINTONPHARM
1.12.2021 14:02:14 CET | Business Wire | Press release
LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T cell engaging bispecific antibodies for cancer immunotherapy, today announced that the first patient has been dosed in the Company’s Phase 1/2 clinical trial program for catumaxomab (clinicaltrials.gov: NCT04799847 ), a monoclonal bispecific antibody being studied for the treatment of Non-Muscle-Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).
“The initiation of our Phase 1 trial of catumaxomab for the treatment of NMIBC is an important step in our clinical program evaluating catumaxomab as targeted therapy in a broad range of cancers”, said Robert Li, PH.D., DABT, Co-founder and CEO of LintonPharm. “Patients with NMIBC BCG failure need new therapies due to the limitations of current treatments which bring poor prognosis, such as high rates of tumor recurrence, bladder dysfunction and lifelong intervention. Based on encouraging pre-clinical data and clinical experience with patients who’ve received catumaxomab in the past through the compassionate use program, we are hopeful that catumaxomab will be a very promising immunotherapy candidate for patients with NMIBC BCG failure.”
A recent publication indicated clinical benefits of catumaxomab as compassionate use in patients with EpCAM-positive recurrent NMIBC. It is noted that catumaxomab was well tolerated and presented promising performance in tumor control [1] . Based on the data and the developmental potential, catumaxomab could provide a feasible, safe, and efficacious therapy for NMIBC patients, if approved.
Bladder cancer is the 10th most commonly diagnosed cancer worldwide, with approximately 573,000 new cases in 2020 and roughly 75 percent are diagnosed as NMIBC [2][3] . Currently, the mainstay treatments of NMIBC include transurethral resection, chemotherapy and intravesical BCG [3] .
About Catumaxomab
Catumaxomab was approved by the European Medicines Agency in 2009 for the treatment of malignant ascites. This bispecific antibody binds to a transmembrane glycoprotein on the tumor cell--the epithelial cell adhesion molecule (EpCAM)--and CD3 on the T cell, and also recruits immune accessory cells through FcγR binding. Catumaxomab destroys tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models.
Recently, catumaxomab was authorized by regulatory authorities in China, Taiwan (China) and South Korea to conduct a global Phase 3 clinical trial for treating patients with advanced gastric cancer (clinicaltrials.gov: NCT04222114 ).
About LintonPharm
LintonPharm Co., Ltd. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of turning malignant cancers into manageable and possibly curable diseases. LintonPharm has developed multiple bispecific antibody platforms with a great potential of refined safety and efficacy profiles, long-lasting vaccinal effects and CMC efficiency. The current pipeline includes several treatments in development for blood cancer and solid tumors. The leading molecule, catumaxomab is being evaluated in clinical trials for both advanced gastric cancer and non-muscle invasive bladder cancer. For more information, please visit www.lintonpharm.com .
[1]. Ruf P, Bauer HW, Schoberth A, Kellermann C, Lindhofer H (2021). First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non muscle invasive bladder cancer indicates high tolerability and local immunological activity. Cancer Immunology, Immunotherapy. http://doi.org/10.1007/s00262-021-02930-7 |
[2]. World Health Organization (WHO). Globocan 2020. Global Cancer Observatory. Accessed January 7, 2021. https://gco.iarc.fr/ |
[3]. Kamat AM, Hahn NM, Efstathiou JA, et al. (2016) Bladder cancer. Lancet 2016. 388: 2796-810. http://dx.doi.org/10.1016/S0140-6736(16)30512-8 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005307/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cyclic Materials Appoints Tomasz Poznar as Chief Commercial Officer to Accelerate Global Commercial Growth16.7.2026 15:20:00 CEST | Press release
Industry leader in critical materials and battery recycling to drive Cyclic’s global commercial growth and strategic partnerships. Cyclic Materials, the rare earth recycling company building a circular supply chain for rare earth elements and critical materials, today announced the appointment of Tomasz Poznar, Ph.D., as Chief Commercial Officer. The appointment strengthens Cyclic Materials’ executive team as the company accelerates commercial expansion across North America, Europe, and Asia. Most recently, Poznar served as Chief Commercial Officer at Ascend Elements, where he led the company’s global commercial strategy, strategic partnerships, and business development. During his tenure, he helped secure more than USD $1.5 billion in commercial agreements, including a landmark USD $1 billion supply agreement with a major global automaker, while also supporting approximately USD $320 million in TCTF government funding that accelerated the company’s growth in North America and Europe.
Modon Holding and Nammos Hotels & Resorts Bring Nammos Ras El Hekma to Egypt’s North Coast16.7.2026 14:50:00 CEST | Press release
Developed in partnership with Nammos Hotels & Resorts, the landmark Mediterranean destination will bring together branded residences, a luxury resort, restaurant and beach club, retail village, and signature dining and wellness experiences to Egypt for the first time. Abu Dhabi-based Modon Holding and Nammos Hotels & Resorts have announced Nammos Ras El Hekma – the renowned lifestyle and hospitality brand’s first fully integrated destination in Egypt. Located within the Wadi Yemm precinct, the development will bring Ras El Hekma’s promise of timeless Mediterranean living to life, combining Nammos Residences, Nammos Resort, Nammos Village, and a curated selection of all-day dining and wellness experiences, including the globally renowned Nammos Restaurant & Beach Club. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716740934/en/ Modon Holding and Nammos Hotels & Resorts bring Nammos Ras El Hekma to Egypt’s North Coast (Pho
Tridiagonal.ai (T.AI) Partners with PETRONAS Carigali’s TriCipta AI with IBM to Advance Engineering Domain-Driven AI Solutions for Upstream Operations16.7.2026 14:30:00 CEST | Press release
Tridiagonal.ai will contribute engineering domain-driven AI solutions, physics-informed models and Decision Intelligence capabilities to support upstream surface equipment optimisation, maintenance reliability and asset integrity decision workflows. Tridiagonal.ai Pvt. Ltd. (T.AI), the dedicated AI arm of Tridiagonal Group, announced its role in the third Joint Development Agreement (JDA) involving PETRONAS Carigali Sdn. Bhd. and IBM Malaysia Sdn. Bhd. to advance PETRONAS Carigali’s flagship TriCipta AI across the Upstream value chain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260715579933/en/ Signing ceremony for the third TriCipta AI Joint Development Agreement, attended by executives from Tridiagonal.ai (T.AI), PETRONAS Carigali, and IBM Malaysia. TriCipta AI is PETRONAS Carigali’s partnership model that combines deep domain technical expertise with advanced AI technology experts to accelerate the development and dep
Crown Bioscience Joins C-Path's NAMs Developer Coalition to Advance Human-Relevant Models in Drug Development16.7.2026 14:30:00 CEST | Press release
Global CRO brings patient-derived models, organoid platforms and biomarker expertise to collaborative effort advancing regulatory acceptance of New Approach Methodologies Crown Bioscience is a global contract research organization (CRO) specializing in oncology drug discovery and development, today announced it has joined Critical Path Institute's (C-Path) New Approach Methodologies Developer Coalition (NAMs-DC), a collaborative initiative dedicated to advancing the validation, qualification and regulatory adoption of innovative human-relevant research methods. Crown Bioscience joins a growing community of technology developers, pharmaceutical companies, regulatory stakeholders and scientific experts working to accelerate the adoption of New Approach Methodologies (NAMs) across drug discovery and development. Through its participation in NAMs-DC, Crown Bioscience will contribute expertise spanning patient-derived xenograft (PDX) models, patient-derived tumor organoids, ex vivo patient
Silo Communications expands fiber connectivity in rural Illinois with Adtran16.7.2026 14:00:00 CEST | Press release
News summary: Silo Communications needed a scalable fiber access platform to bring faster, more reliable broadband to underserved communities With Adtran’s technology and intelligent software, Silo Communications is strengthening service delivery as it evolves from wireless to fiber Deployment supports wider state and federal efforts to close the digital divide and create a foundation for long-term rural growth Adtran today announced that Silo Communications, a rural broadband provider based in northern Illinois, is using its fiber access portfolio and software applications to expand high-speed connectivity for underserved homes and businesses. As demand for reliable broadband continues to grow across communities, Silo Communications is building on its wireless heritage with a scalable fiber network designed to support higher speeds, stronger service reliability and future expansion. The deployment supports wider state and federal efforts to extend high-speed connectivity to underserve
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom